slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 40,531-40,560
Pages 2,019
Rows per page 30
Component
40,531-40,560 of 60,568
04
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Situation & Context1 hit
05
The slide uses a Gantt-style visualization to show the development status of various drug candidates.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
12
The slide uses a Gantt-style visualization to show the progression of various drug programs (SPY001-SPY230).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
13
The slide uses a matrix-like layout to map strategy (mAbs vs combinations) to specific programs and their development status (Discovery, IND-Enabling, Clinical).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
16
The table uses checkmarks for positive attributes and arrows for 'potential upside' to differentiate SPY001's superior profile.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
17
The slide uses a Y-shaped antibody diagram to annotate specific functional improvements.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
19
The chart shows dose-response curves for cell binding. The table summarizes EC50 values.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
29
Uses a checkmark matrix to highlight competitive advantages of SPY002.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
30
The slide uses an antibody diagram to annotate specific technical advantages of the SPY002 molecule.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
33
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
38
The slide uses a bar chart to illustrate additive clinical remission rates, with a table below providing additional clinical metrics (N, maintenance remission, safety).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
39
The slide uses donut charts to represent remission rates and highlights the safety advantages of Spyre's gut-selective approach.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
46
The slide uses a table-based timeline format to track R&D progress and external data readouts.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
47
The table uses a custom visualization for market cap range (min, IPO, today, max) and clinical stage progression.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
48
The table maps historical industry M&A deals to Spyre's internal pipeline development milestones (2025-2027).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
04
The slide uses a contrast-pairs framework to differentiate the company from traditional retail incumbents.a.k.a. Brands | Investor Presentation Deck | 13 slides · a.k.a. Brands
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
05
The slide uses a table-like structure to map strategic pillars to operational outcomes.a.k.a. Brands | Investor Presentation Deck | 13 slides · a.k.a. Brands
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
03
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
10
The slide uses a numbered list format to map strategic pillars to specific results.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)Loop · Before After1 hit
15
The slide highlights board changes, including specific appointments with shareholder support and the addition of diverse skill sets.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
17
The table categorizes products into 'Proprietary' and 'Royalty' streams.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
29
The slide uses a table-like structure to compare four board members.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
30
The slide uses a structured table format to map committees to their specific oversight domains.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
31
Includes a specific quote from an ISS recommendation regarding majority voting standards.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
37
The slide uses a red-themed table to highlight negative attributes of specific individuals.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
38
The slide uses a table-like structure to present a timeline of legal events and critical court commentary.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
39
The slide uses a checkmark matrix to demonstrate board competency across five key areas: Neuroscience, Financial/Transactional, Commercial, Medical/R&D, and Global Business.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
40
This is a proxy fight slide comparing incumbent board members against challenger nominees.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
10
Includes a non-GAAP disclaimer footnote.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations Beat · Financials1 hit
19
The table includes footnotes (1-8) for specific line items.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit